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To evaluate the efficacy and toxicity of the sequential nonplatinum combination chemotherapy consisting of gemcitabine (GEM) and
vinorelbine (VNR) followed by docetaxel (DOC) in patients with advanced non-small-cell lung cancer (NSCLC), we conducted the
multiinstitutional phase II study. A total of 44 chemotherapy-naive patients with advanced NSCLC were treated with GEM
1000mgm
 2 and VNR 25mgm
 2 intravenously on days 1 and 8 every 3 weeks for three cycles. DOC 60mgm
 2 was then
administrated intravenously at 3-week intervals for three cycles. Patients were evaluated for response and toxicity with each cycle of
the treatment. The major objective response rate was 47.7% (95% confidence interval (CI), 33.8–62.1%). Median survival time (MST)
was 15.7 months and 1-year survival rate was 59%. In the GEM/VNR cycle, grade 3/4 neutropenia occurred in 36.3%, grade 3/4
anaemia in two patients (4.5%) and grade 3 thrombocytopenia in one patient (2.3%). Grade 3 pneumonitis occurred in two patients
(4.5%) in GEM/VNR cycles. In the DOC cycles, grade 3/4 neutropenia occurred in 39.4% but no patient experienced grade 3/4
anaemia or thrombocytopenia. Of the 44 eligible patients, 33 patients completed three cycles of GEM/VNR and 22 patients
completed six cycles of planned chemotherapy (three cycles of GEM/VNR followed by three cycles of DOC). The sequential triplet
nonplatinum chemotherapy consisted of GEM/VNR followed by DOC, and was very active and well tolerated. This study forms the
basis for an ongoing phase III trial that compares this nonplatinum triplet and standard platinum doublet combination (carboplatin/
paclitaxel).
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Lung cancer represents a major cause of cancer death in many
countries and approximately 80% of all these patients are
categorised as non-small-cell lung cancer (NSCLC) (Fry et al,
1996). Cisplatin (CDDP)-containing chemotherapy has been
shown to have certain benefits in the survival of patients with
advanced NSCLC (NSCLC Cooperative Group, 1995). However,
combination chemotherapy containing CDDP has significant
toxicities, including severe nausea, vomiting and renal toxicity
requiring adequate hydration, which increases the difficulty in the
treatment of the elderly or outpatients. In previous randomised
studies, CDDP-containing combinations have proved more toxic
than those without cisplatin (Luedke et al, 1990; Gridelli et al,
1996; Georgoulias et al, 2001). Carboplatin is a platinum without
the toxic disadvantages of CDDP; however, this agent still causes
nausea, vomiting and myelosuppression. New active agents such as
taxanes, gemcitabine (GEM), vinorelbine (VNR) and topoisome-
rase-I inhibitors have been tested in NSCLC with encouraging
results, and several nonplatinum combinations have been devel-
oped. Among the new drugs, GEM/VNR combination is note-
worthy because of their demonstrated activity and particularly
their good toxicity profile. This combination can also be used for
elderly or unfit patients, because of its low toxicities (Feliu et al,
1999; Isokangas et al, 1999; Bajetta et al, 2000; Beretta et al, 2000;
Gridelli et al, 2000). In addition, it has been shown that a single
treatment of docetaxel (DOC) is active for NSCLC, especially as a
second-line treatment (Fossella et al, 2000; Shephard et al, 2000).
This led to the hypothesis that DOC may be effective for the
resistant clones against first-line chemotherapy. A small amount of
residual resistant clones can be eradicated by sequential admin-
istration of DOC before these clones grow and relapse. Some
studies showed that a combined chemotherapy of three agents
(triplet) may prove to be superior to that of two agents (doublet)
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l(Comella et al, 2000). However, concurrent administration of
triplet combination requires the reduction of dose because
of toxicities, and subsequently may cause the reduction of
effectiveness. Theoretical modelling of Norton–Simon (1986)
clearly indicates that cell kill can be substantially increased
by the sequential use of cytotoxic regimens. However, the
Norton–Simon hypothesis has only been validated in a minority
of cancer treatment strategies. The dose of GEM/VNR combination
was determined according to several phase II trials, especially
the Italian study that compared three different doses (Gridelli
et al, 2000). A 60mgm
 2 of DOC was the recommended dose
in a Japanese phase I study. Japanese phase II studies were
carried out at this dose and were not inferior when compared
with several studies with more than 70mgm
 2 of DOC. Regarding
the number of cycles, an average of 3–4 cycles per patient
were given in two phase III studies of second-line DOC (Fossella
et al, 2000; Shephard et al, 2000). It has been reported that no
additional benefits were observed by continuing chemotherapy
beyond three cycles (Smith et al, 2001). Based on this collective
background, we conducted this phase II trial of a sequential
nonplatinum triplet combination consisting of three cycles of GEM
(100mgm
 2) and VNR (25mgm
 2) followed by three cycles of
DOC (60mgm
 2).
PATIENTS AND METHODS
Patient eligibility
Chemotherapy-naı ¨ve patients with Eastern Cooperative Oncology
Group (ECOG) performance status (PS) 0–1, over 18 years old,
with stage IV and IIIB (with malignant pleural effusion and/or
pulmonary nodule(s) that the same lobe of the primary lesion)
NSCLC were eligible. The upper limit of age was not defined.
Patients had unidimensionally measurable disease. Exclusion
criteria were the presence of apparent interstitial pneumonitis,
massive pleural effusion requiring thoracenthesis, uncontrollable
diabetes mellitus, heart diseases, history of another cancer
(excluding nonmelanomatous skin cancer and in situ cervical
cancer), reduced bone marrow, pulmonary, renal or hepatic
function. Stage IIIB patients with pulmonary nodule(s) at the
same lobe of the primary lesion were ineligible if they could be
considered as an indication of radiation therapy or operation. CNS
metastases were not considered as an exclusion criterion if
asymptomatic. All patients gave written informed consent. The
study protocol was approved by the ethical committees of Japan
Multinational Trial Organization (JMTO) and the participating
institutions.
Treatment plan
Within 7 days before entry in the study, all patients underwent a
complete medical history, physical examination, urine, haemato-
logic and biomedical testing. Within 4 weeks, clinically indicated
scans, including computed tomography of the chest, abdomen (or
abdominal ultrasound), brain (or magnetic resonance imaging of
the brain) and radionuclide bone scans, electrocardiogram, arterial
blood gas and pulmonary function tests were performed. Patients
received GEM 1000mgm
 2 and VNR 25mgm
 2 on days 1 and 8
every 21 days for three cycles. Single-agent DOC 60mgm
 2 was
then given on day 1 every 21 days for three cycles. Premedications
such as antiemetic agents or corticosteroids were given at the
investigator’s discretion. Prophylactic granulocyte-colony stimu-
lating factor (G-CSF) was not allowed at any treatment cycle.
During the DOC cycle, all patients received 8mg of dexamethasone
just before the administration of DOC. Complete blood cell count
was checked on the day of each planned treatment. During the
GEM/VNR cycle, a liver function test (AST and ALT) was also
administrated. If WBC count was below 3000mm
 3, platelet
count was below 75000mm
 3, or AST/ALT was over 100IUl
 1 on
day 1 of each cycle, GEM/VNR administration was delayed
by a week. If WBC count was below 2000mm
 3, platelet count
was below 50000mm
 3 or AST/ALT was over 100IUl
 1, admin-
istration of GEM/VNR on day 8 was discontinued. If WBC count
was below 3000mm
 3 or platelet count was below 75000mm
 3 at
day 1 of the cycle, DOC administration was delayed by a week.
Toxicity evaluations were based on the National Cancer Institute’s
Common Toxicity Criteria (NCI-CTC), Version 2.0. Treatment
dose was reduced to 80% of prior treatment dose if there were
grade 4 leukocytopenia, neutropenia or platelet counts below
20000mm
 3, other unacceptable toxicities including grade 3
neutropenic fever or grade 3 or more nonhaematological toxicities
other than nausea, vomiting, fatigue or alopecia, during the
preceding treatment cycle. A full dose of DOC was administrated
on day 1 of the first DOC cycle, even if elevated toxicities were
observed in the prior GEM/VNR cycles. The dose of DOC was
reduced to 80% only when the above toxicities were observed by
prior administration of DOC. Patients went off-study with a
treatment delay of greater than 2 weeks or with progressive
disease. Protocol treatment was also discontinued when patients
had grade 2 pneumonitis or other severe toxicities that made it
difficult to continue the protocol treatment. Patients were
monitored and evaluated weekly for toxicities and monthly for
response. Response evaluation criteria in solid tumor (RECIST)
(Therasse et al, 2000) was used for the evaluation of response. An
extramural review of all treated patients was performed for the
response evaluation.
Statistical methods
In accordance with the optimal two-stage phase II design (Simon,
1989), the treatment programme was designed to reject a response
rate of less than 20% (p0) and provide a statistical power of 85% in
assessing the activity of the regimen as 40% (p1) (p1 p0¼20%)
with an alpha error of less than 0.05 and a beta error of less than
0.10. Therefore, 40 patients were required: 22 for the first step and
18 for the second. Survival was calculated from the day of
registration to the day of death using the Kaplan–Meier method
(1958).
RESULTS
A total of 45 patients were enrolled from 17 participating
institutions between April and November 2000. After registration,
one patient was excluded because he was proved to be stage 1
and had an operation. Patient characteristics are listed in
Table 1. Of the 44 eligible patients, there were 28 men and 16
women, with a median age of 63 years (range, 41–81 years). The
majority of the patients had stage IV disease and ECOG PS of 1.
The results for response rate, toxicity profile and survival were
analysed on September 2001. As shown in Table 2, 33 (75%) out of
44 patients received three cycles of GEM/VNR, and during the
DOC cycle, 22 (76%) out of 29 patients completed three cycles of
DOC. Of 44 patients, 11 patients went off the protocol during GEM/
VNR cycle (seven patients had progressive disease, two patients
had pneumonitis, one had treatment delay more than 2 weeks
because of grade 2 hepatic dysfunction and one patient withdrew
informed consent). Of 33 patients who completed three cycles of
GEM/VNR, four patients went off the protocol just before the DOC
cycle (two patients had progressive disease and two patients
withdrew informed consent). Accordingly, 29 out of 44 registered
patients (66%) went to DOC cycle. During DOC cycle, seven out of
29 patients went off protocol (three patients withdrew informed
consent, one had progressive disease, two had treatment delay
because of myelosuppression, one had grade 2 pneumonitis).
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lTherefore, 22 out of 44 (50%) patients completed six cycles of
chemotherapy. The average cycle number of chemotherapy
was 4.5 cycles per patient. As a whole, there were no complete
response (CR), 21 partial response (PR), 17 stable disease (SD) and
six progressive disease (PD). The best overall response rate was
47.7% with 95% CI: 31.8–61.4%. MST was 15.7 months (¼471
days, 95% CI: 270 days to not yet reached) with a mean follow-up
time of 374.5 days. The 1-year survival rate was 59% and the
Kaplan–Meier survival curve is displayed in Figure 1. The survival
data were analysed in October 2001, at which time, 22 patients had
died and 22 were alive. The toxicity profile is shown in Table 3.
There were no treatment-related deaths. Grade 3/4 neutropenia
was seen in 36.3 and 39.4% in GEM/VNR and DOC cycle,
respectively. There were only two patients (4.5%) and one patient
(2.3%) who experienced grade 3/4 anaemia and thrombocytope-
nia, respectively. In nonhaematologic toxicities, two patients
(4.5%) had grade 3 pneumonitis during the GEM/VNR cycle.
Other toxicities were infrequent and generally acceptable. A mild
elevation of AST/ALT was seen occasionally in the GEM/VNR
cycle, but except for one patient (grade 3) most occurrences were
in grade 1/2 and all of them recovered without treatment. There
was no neurological toxicity corresponding to grade 3/4, but six
patients experienced grade 1 during the GEM/VNR cycle (data not
shown).
DISCUSSION
The recent development of new anticancer drugs, which have
almost equal activity against NSCLC but are less toxic compared to
CDDP, provides alternatives to CDDP (Georgoulias et al, 2001). In
particular, a GEM/VNR combination was very well tolerated with
high activity (Feliu et al, 1999; Isokangas et al, 1999; Bajetta et al,
2000; Beretta et al, 2000; Gridelli et al, 2000). The Spanish Lung
Cancer Group (Alberola et al, 2001) reported on a randomised
comparison of a CDDP-based three-drug combination (CDDP/
GEM/VNR) vs non-CDDP sequential doublets (GEM/VNR followed
by ifosphamide/VNR) vs CDDP/GEM (reference regimen). There
were no survival differences among the three arms, and it was
concluded that the triplet combination including CDDP showed no
advantage since the toxicity profile of this arm was worst. This
result is contrary to that of an Italian phase III study by Comella
et al (2000). The best toxicity profile in the Spanish study was seen
Table 1 Patient characteristics
Characteristics No. %
Total 44 100
Sex
Male 28 63.6
Female 16 36.4
Age (years)
Median (range) 63 (44–81)
o70 36 81.8
X70 8 18.2
ECOG performance status
0 9 20.5
1 35 79.5
Histology
Adenocarcinoma 29 65.9
Squamous cell 10 22.7
Large cell 5 11.4
Stage
IIIB 9 20.5
IV 35 79.5
No. of distant metastases
0 9 20.5
1 24 54.5
2 7 15.9
3 3 6.8
X4 1 2.3
ECOG=Eastern Cooperative Oncology Group.
Table 2 Reasons and timing for treatment discontinuation
GEM/VNR DOC
Cycle no. 1 2 3 4 5 6 Total
Progressive disease 0 3 4 2 0 1 10
Adverse event 0 1 2 0 1 2 6
Patient’s refusal 0 1 0 2 2 1 6
22
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Figure 1 Kaplan–Meier survival curve is shown. With a mean follow-up
of 374.5 days, the predicted median survival time is 15.7 months and the
1-year survival rate is 59%.
Table 3 Frequency of toxicities (worst toxicities per patient) during the
first three cycles (GEM/VNR) and the latter three cycles (DOC)
GEM/VNR (n=44) DOC (n=33)
Grade3 (%) Grade4 (%) Grade3 (%) Grade4 (%)
Haematologic
Neutrophils 20.4 15.9 15.2 24.2
Haemoglobin 2.3 2.3 0 0
Platelets 2.3 0 0 0
Nonhaematologic
Nausea, vomiting 2.3 0 3.0 0
Febrile neutropenia 2.3 0 0 0
Pneumonitis 4.5 0 0 0
Fatigue 4.5 0 0 0
Hepatic dysfunction 2.3 0 0 0
Hyponatremia 2.3 0 0 0
Hypopotassemia 2.3 0 0 0
Haematuria 2.3 0 0 0
GEM/VNR followed by DOC for advanced NSCLC
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lin the arm without CDDP (GEM/VNR followed by ifosphamide/
VNR), a sequential combination. There is still some anxiety for the
combination without CDDP whether it may lose its power of
chemotherapy; however, there have been some encouraging
reports without CDDP for NSCLC. Pectasides et al (1999) reported
a triplet combination of carboplatin, DOC and GEM for NSCLC
with a response rate of 46.5% and MST of 13.5 months. Another
report by Miller et al (2000) showed a response rate of 51% and a
1-year survival of 60% by DOC and VNR. Both these phase II
studies showed high response rates and good survival, but febrile
neutropenia was seen in 13–14% of the patients even though both
studies used prophylactic G-CSF and the latter study used
prophylactic ciprofloxacin, as well. In the present study, only
one patient (2%) developed febrile neutropenia, but we did not use
prophylactic G-CSF or antibiotics. Furthermore, in contrast to
conventional platinum-based chemotherapy in which most
patients experience nausea, vomiting and fatigue, only a limited
number of patients had these toxicities in this nonplatinum triplet
regimen. Although we did not evaluate the quality of life (QoL),
this regimen could in fact prove superior to conventional
platinum-based regimens in terms of QoL.
Recently, DOC was shown to be active as a second-line
chemotherapy (Fossella et al, 2000; Shephard et al, 2000). On the
assumption that the tumour is composed of subpopulations of
cells with differing patterns of resistance and growth kinetics, DOC
may be effective against the tumour population of refractory but
slower-growing cells. Therefore, sequential administration of DOC
following other agents as a first-line may strike the refractory
population before they grow and become apparent. Another
rationale for exploring sequential therapy is optimising dose
delivery. The concept for the sequential administration of full-dose
chemotherapeutic agents having different mechanisms of action is
supported by the Norton–Simon hypothesis (1986). Manegold et al
(2001) reported on a sequential administration of single-agent
GEM and DOC. Although it was a randomised phase II study, they
reported that a 4 weekly GEM–DOC sequence was better than a
DOC–GEM sequence, in terms of survival. However, sequential
but monotherapy may not be viewed positively since the response
rate was 5–11% and the 1-year survival was 19–30% in their
study. Recently, Edelman et al (2001a) reported the results of
phase II study for sequential combination chemotherapy consist-
ing of carboplatin and GEM followed by paclitaxel showed modest
activity (overall response: 31%, median survival time: 9.5 months).
Based on the results of this study, Southwest Oncology Group
(SWOG) has completed a randomised phase II trial of two
sequential combinations (CDDP/VNR followed by DOC vs
carboplatin/GEM followed by paclitaxel) and reported that both
arms had comparable activity (response rate: 21 and 28%, 1-year
survival: 32 and 31%) (Edelman et al, 2001b). The concept of this
SWOG study which involved a doublet followed by taxane, is
similar to that of the present study. However, both arms of the
SWOG study included platinum in the front line, so that the
toxicity profile was comparatively worse. In the present study, 21
out of 44 patients showed PR. In all, 17 patients showed PR in the
GEM/VNR cycle and four patients in the DOC cycle (data not
shown). Tumours in some patients began to decrease in size
during the GEM/VNR cycles and lasted through the DOC cycles. It
is possible to consider that not only GEM/VNR but also DOC was
effective in these patients. One patient went off-study in the GEM/
VNR cycle because of treatment delay caused by prolonged
hepatotoxicity. This patient had a PR by the DOC administration.
Another patient who went off-study in the GEM/VNR cycle
because of disease progression had a PR by the DOC administra-
tion. Although the response in these two patients were evaluated as
SD and PD, but not as PR because the response was seen when the
patients were off-study, sequential administration of DOC seems to
be also effective for patients with resistant, or unfit, to other
chemotherapeutic agents.
The best overall response rate in this study was 47.7% (95% CI:
31.4–61.8%). Median survival time was 15.7 months and the 1-year
survival rate was 59%. These results are encouraging and may be
one of the highest reported for advanced NSCLC. It should be
pointed out that this finding, especially survival data, might have
been influenced by patient selection. In this study, patients’ PS
might be relatively better than other trials. Although 80% of the
patients were at stage IV, 83% of them had less than two sites of
distant metastasis (Table 1). Furthermore, only three of them had
solitary brain metastasis (data not shown) that was relatively small
in size and asymptomatic. None of them were treated with cranial
irradiation. There were no treatment-related deaths. Toxicities
were mild and acceptable, with approximately one-third of patients
showing grade 3/4 neutropenia, and only one and two patients
showing grade 3/4 thrombocytopenia and anaemia, respectively.
Most nonhaematological toxicities were mild and infrequent.
However, there were two patients who experienced grade 3
pneumonitis in the GEM/VNR cycle. They received corticosteroid
treatment and recovered in a couple of months, but both patients
went into best supportive care. Even though this toxicity may be a
rare event, attention should be paid since this can be life
threatening. In a phase II study of three different doses of GEM/
VNR in Italy (Gridelli et al, 2000), a grade 3 pneumonitis was
observed in dose level II but not in dose level III, suggesting that
this adverse effect is not dose dependent. There were eight patients
aged over 70 years in our study. In these eight elderly patients, five
patients (62.5%) completed six cycles of chemotherapy, and the
response rate was 62.5% (95% CI: 25–87.5%). Therefore, this
regimen seems apt for including elderly patients because of its high
response rate and low toxicities. The results of Multicentre Italian
Lung Cancer in the Elderly Study (MILES) showed that combina-
tion chemotherapy (GEM/VNR) was not superior to monotherapy
(VNR) for elderly NSCLC patients (Gridelli et al, 2001), contrary to
the Southern Italy Cooperative Oncology Group (SICOG) results
(Frasci et al, 2000). In their studies, the administration dose of
chemotherapy was higher than ours, so the toxicity profile was
worse. They included patients with PS 2. At the decision for the
recommended dose for phase II trial, the maximum tolerated dose
as determined by the phase I study was sometimes chosen because
investigators usually believe that a higher dose of chemotherapy
makes for better efficacy. In the Italian phase II study of three
different doses of GEM/VNR (Gridelli et al, 2000), however, the
higher dose caused higher toxicities but no significant additional
efficacy. Two phase III trials of second-line DOC (Fossella et al,
2000; Shephard et al, 2000) also showed that the arm of 75mg of
DOC was significantly better than that of 100mg, in terms of
survival. Therefore, regimens with doses considered adequate but
not at maximum dose levels of multiple agents may be sufficient
for NSCLC patients, including the elderly. Recently, Baldini et al
(2001) reported the activity and safety of a nonplatinum-based
triplet in advanced NSCLC. They reported 52% of response rate
and 46.5% of 1-year survival but concurrent administration of
three agents made a worse toxicity profile.
In conclusion, the nonplatinum sequential triplet regimen
consisting of GEM/VNR followed by DOC is very attractive
because of its high activity and low toxicity profile. This seems
suitable for the elderly and outpatients, as well. We want to remark
that the present study is the first report of nonplatinum sequential
triplet chemotherapy against NSCLC. This study serves as the basis
for an ongoing randomised phase III trial (JMTO LC00-03) that
compares this regimen with carboplatin/paclitaxel. The major aim
of this phase III study is to determine whether nonplatinum
sequential triplet is superior to platinum doublet. The results of
this study may also answer the question of whether or not
platinum is essential to front-line chemotherapy for advanced
NSCLC. The study, JMTO LC00-03, was begun in April 2001, in
collaboration with SWOG 0003 trial (carboplatin/paclitaxel7tir-
apazamine), using the same protocol for common control arm
GEM/VNR followed by DOC for advanced NSCLC
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l(carboplatin/paclitaxel). In addition, it may also prove interesting
if some determination of the ethnic background of patients might
influence the chemotherapeutic effect and/or adverse effects on
standard combination chemotherapy for advanced NSCLC.
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